Belite Bio Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
Belite Bio is a San Diego-based biotechnology research company focused on clinical-stage drug development for degenerative retinal diseases and metabolic disorders. Its lead candidate Tinlarebant (LBS-008) is an oral, once-daily tablet intended to treat early-stage dry AMD and Stargardt disease (STGD1). Tinlarebant is in Phase 3 and has received regulatory designations including US Fast Track and Rare Pediatric Disease (RPD), as well as Orphan Drug Designation in the US and from the EMA for STGD1. Belite Bio trades on the NASDAQ as BLTE and is headquartered at 5820 Oberlin Drive Suite 101, San Diego, CA 92121, United States. The company has 51-200 employees and has reported revenue in the range of $10 million to $25 million, with funding around $125 million.